TY - JOUR
T1 - Gene therapy for arthritis
AU - Robbins, P. D.
AU - Evans, C. H.
AU - Chernajovsky, Y.
PY - 2003/5
Y1 - 2003/5
N2 - Rheumatoid arthritis is an autoimmune disease with intraarticular inflammation and synovial hyperplasia that results in progressive degradation of cartilage and bone, in severe cases it causes systemic complications. Recently, biological agents that suppress the activities of proinflammatory cytokines have shown efficacy as antiarthritic drugs, but require frequent administration. Thus, gene transfer approaches are being developed as an alternative approach for targeted, more efficient and sustained delivery of inhibitors of inflammatory cytokines as well as other therapeutic agents. Indeed, the efficacy of gene transfer for the treatment of arthritis has been demonstrated in mouse, rat, rabbit, and horse models of disease whereas the feasibility of the approach has been demonstrated in Phase I clinical trials. In this review, the current status of both preclinical and clinical arthritis gene therapy is presented. In addition, the advantages and disadvantages of different types of vectors, target cells and therapeutic genes being developed for the treatment of arthritis are summarized. Finally, the future directions of the rapidly developed field of arthritis gene therapy are outlined.
AB - Rheumatoid arthritis is an autoimmune disease with intraarticular inflammation and synovial hyperplasia that results in progressive degradation of cartilage and bone, in severe cases it causes systemic complications. Recently, biological agents that suppress the activities of proinflammatory cytokines have shown efficacy as antiarthritic drugs, but require frequent administration. Thus, gene transfer approaches are being developed as an alternative approach for targeted, more efficient and sustained delivery of inhibitors of inflammatory cytokines as well as other therapeutic agents. Indeed, the efficacy of gene transfer for the treatment of arthritis has been demonstrated in mouse, rat, rabbit, and horse models of disease whereas the feasibility of the approach has been demonstrated in Phase I clinical trials. In this review, the current status of both preclinical and clinical arthritis gene therapy is presented. In addition, the advantages and disadvantages of different types of vectors, target cells and therapeutic genes being developed for the treatment of arthritis are summarized. Finally, the future directions of the rapidly developed field of arthritis gene therapy are outlined.
UR - http://www.scopus.com/inward/record.url?scp=0038146937&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=0038146937&partnerID=8YFLogxK
U2 - 10.1038/sj.gt.3302040
DO - 10.1038/sj.gt.3302040
M3 - Review article
C2 - 12732875
AN - SCOPUS:0038146937
SN - 0969-7128
VL - 10
SP - 902
EP - 911
JO - Gene Therapy
JF - Gene Therapy
IS - 10
ER -